ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Development of oral immunomodulatory agents in the management of multiple sclerosis. Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA Drug Des Devel Ther. 2011; 5:255-74. Epub 2011 May 10. PMID: 21625416. Abstract
Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE Phase 3 clinical trial Biogen Idec, 21 Oct 2011 Accessed on 4 Jan 2012 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1619878.
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner. Loewe R, Pillinger M, de Martin R, Mrowietz U, Gröger M, Holnthoner W, Wolff K, Wiegrebe W, Jirovsky D, Petzelbauer P J Invest Dermatol. 2001 Dec; 117(6):1363-8. PMID: 11886496. Abstract
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, Hoffmann V, Pöhlau D, Przuntek H Eur J Neurol. 2006 Jun; 13(6):604-10. PMID: 16796584. Abstract
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, et al. Lancet. 2008 Oct 25; 372(9648):1463-72. PMID: 18970976. Abstract
Use of fumaric acid esters in psoriasis. Roll A, Reich K, Boer A Indian J Dermatol Venereol Leprol. 2007 Mar-Apr; 73(2):133-7. PMID: 17456929. Abstract
Biogen Idec to acquire Fumapharm AG; Consolidates ownership of oral compound BG-12 being studied for multiple sclerosis Biogen Idec, 31 May 2006 Accessed on 4 Jan 2012 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=862060.
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative--Fumapharm/Biogen Idec. Drugs R D. 2005; 6(4):229-30. PMID: 15991882. Abstract
US and EU regulatory authorities accept oral BG-12 marketing applications for review Biogen Idec, 9 May 2012 Accessed on 16 May 2012 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1694087.
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis Biogen Idec, 24 Apr 2012 Accessed on 16 May 2012 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1686377.
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, et al. Mult Scler. 2012 Mar; 18(3):314-21. Epub 2011 Aug 30. PMID: 21878455. Abstract
Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kcyB (NF-kcyB) and Extracellular Signal-regulated kinase 1 and 2 (ERK1/2) and Mitogen Stress activated kinase 1 (MSK1) signaling. Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, Lovett-Racke AE, Racke MK J Biol Chem. 2012 Jun 25. PMID: 22733812. Abstract
Effects of dimethyl fumarate on neuroprotection and immunomodulation. Albrecht P, Bouchachia I, Zimmermann C, Hofstetter HH, Kovacs Z, Henke N, Lisak D, Issberner A, Lewerenz J, Maher P, et al. J Neuroinflammation. 2012 Jul 7; 9(1):163. Epub 2012 Jul 07. PMID: 22769044. Abstract
Editors' Pick Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. Fox RJ, Miller DH, Phillips TJ, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, et al. N Engl J Med. 2012 Sep 20; 367(12):1087-97. Epub 1969 Dec 31. PMID: 22992072. Abstract
Editors' Pick Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, et al. N Engl J Med. 2012 Sep 20; 367(12):1098-107. Epub 1969 Dec 31. PMID: 22992073. Abstract
New data from Phase 3 studies provide additional evidence supporting treatment effect for oral BG-12 (dimethyl fumarate) in multiple sclerosis Biogen Idec, 12 Oct 2012 Accessed on 16 Oct 2012 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1744697.
Biogen Idec receives notification of PDUFA date extension Biogen Idec, 18 Oct 2012 Accessed on 1 Nov 2012 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1747042.
Biogen slips as FDA extends review of MS drug CBSNews.com, 19 Oct 2012 Accessed on 1 Nov 2012 from http://www.cbsnews.com/8301-505245_162-57536324/biogen-slips-as-fda-extends-review-of-ms-drug/.
US patent office grants patent claiming dosing regimen for TECFIDERA™ (dimethyl fumarate) 19 Mar 2013 Accessed on 21 Mar 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1798029.
CHMP issues positive opinion for TECFIDERA™ (dimethyl fumarate) as a first-line treatment for multiple sclerosis in the European Union Biogen Idec, 22 Mar 2013 Accessed on 25 Mar 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1799179.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis Biogen Idec, 27 Mar 2013 Accessed on 5 Apr 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1801165.
MS research gears up for new drugs Gever J, MedPage Today, 26 Mar 2013 Accessed on 5 Apr 2013 from http://www.medpagetoday.com/clinical-context/MultipleSclerosis/38102.
PML in a patient treated with fumaric acid. Ermis U, Weis J, Schulz JB N Engl J Med. 2013 Apr 25; 368(17):1657-8. PMID: 23614603. Abstract
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP N Engl J Med. 2013 Apr 25; 368(17):1658-9. PMID: 23614604. Abstract
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. Hutchinson M, Fox RJ, Miller DH, Phillips TJ, Kita M, Havrdova E, O'Gorman J, Zhang R, Novas M, Viglietta V, et al. J Neurol. 2013 Jun 8. PMID: 23749293. Abstract
Editors' Pick Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, O'Gorman J, Stephan M, Dawson KT J Neurol. 2013 Jun 25. Epub 2013 Jun 25. PMID: 23797999. Abstract
Dimethyl fumarate regulates histone deacetylase expression in astrocytes. Kalinin S, Polak PE, Lin S X, Braun D, Guizzetti M, Zhang X, Rubinstein I, Feinstein DL J Neuroimmunol. 2013 Aug 2. PMID: 23916696. Abstract
New TECFIDERA® (dimethyl fumarate) data show sustained efficacy and long-term safety in a broad range of multiple sclerosis patients Biogen Idec, 4 Oct 2013 Accessed on 4 Oct 2013 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1861556.
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Kita M, Fox RJ, Phillips TJ, Hutchinson M, Havrdova E, Sarda SP, Agarwal S, Kong J, Zhang A, Viglietta V, et al. Mult Scler. 2013 Oct 22. PMID: 24150778. Abstract
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study. Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, et al. Mult Scler. 2013 Nov 4. Epub 2013 Oct 22. PMID: 24150779. Abstract
Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Sheikh SI, Nestorov I, Russell H, O'Gorman J, Huang R, Milne GL, Scannevin RH, Novas M, Dawson KT Clin Ther. 2013 Oct; 35(10):1582-1594.e9. PMID: 24139424. Abstract
Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism. Dibbert S, Clement B, Skak-Nielsen T, Mrowietz U, Rostami-Yazdi M Arch Dermatol Res. 2013 Mar 25. Epub 2013 Mar 25. PMID: 23525570. Abstract
Editors' Pick Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui M K, Taneja A, Deniz B Curr Med Res Opin. 2013 Nov 7. Epub 1969 Dec 31. PMID: 24195574. Abstract
CHMP determines dimethyl fumarate in TECFIDERA® to be a new active substance in the European Union Biogen Idec, 22 Nov 2013 Accessed on 25 Nov 2013 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1879420.
Anti-inflammatory dimethylfumarate: a potential new therapy for asthma? Seidel P, Roth M Mediators Inflamm. 2013; 2013:875403. Epub 2013 Mar 27. PMID: 23606796. Abstract
Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas. Ghods AJ, Glick R, Braun D, Feinstein D Surg Neurol Int. 2013; 4:160. Epub 2013 Dec 24. PMID: 24404403. Abstract
Effects of fumaric acid esters on blood-brain barrier tight junction proteins. Bénardais K, Pul R, Singh V, Skripuletz T, Lee D-H, Linker RA, Gudi V, Stangel M Neurosci Lett. 2013 Oct 25; 555:165-70. Epub 2013 Sep 26. PMID: 24076006. Abstract
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis 3 Feb 2014 Accessed on 13 Feb 2014 from https://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2286&M=NewsV2&PID=61997.
TECFIDERA prescribing information Biogen Idec, Mar 2013 Accessed on 20 Feb 2014 from http://www.tecfidera.com/pdfs/full-prescribing-information.pdf.
Dimethyl fumarate (BG-12, Tecfidera) - NICE gives initial "no" decision MS Trust, 19 Feb 2014 Accessed on 20 Feb 2014 from http://www.mstrust.org.uk/news/article.jsp?id=6205.
Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1α (HIF-1α). Zhao G, Liu Y, Fang J, Chen Y, Li H, Gao K Biochem Biophys Res Commun. 2014 Feb 22. PMID: 24569076. Abstract
Dimethyl fumarate (BG-12, Tecfidera) approved for use by the NHS in Scotland MS Trust, 7 Apr 2014 Accessed on 8 Apr 2014 from http://www.mstrust.org.uk/news/article.jsp?id=6255.
Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation. Reick C, Ellrichmann G, Thöne J, Scannevin RH, Saft C, Linker RA, Gold R Exp Neurol. 2014 Apr 13. PMID: 24731948. Abstract
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, Köhl J, Offermanns S, Wettschureck N, Schwaninger M J Clin Invest. 2014 Apr 1. PMID: 24691444. Abstract
New data reinforce efficacy of TECFIDERA® (dimethyl fumarate) in MS patients with high disease activity Biogen Idec, 30 Apr 2014 Accessed on 5 May 2014 from https://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2320&M=NewsV2&PID=61997.
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE) ClinicalTrials.gov, 12 Sep 2013 Accessed on 5 May 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01873417.
The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Kawalec P, Mikrut A, Wiśniewska N, Pilc A Curr Neuropharmacol. 2014 May; 12(3):256-68. PMID: 24851089. Abstract
Gastro Effects Dog Oral MS Drug Tecfidera Gever J, MedPage Today, 30 May 2014 Accessed on 5 Jun 2014 from http://www.medpagetoday.com/MeetingCoverage/CMSC-ACTRIMS/46066.
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Gold R, Giovannoni G, Phillips TJ, Fox RJ, Zhang A, Meltzer L, Kurukulasuriya NC Mult Scler. 2014 Jul 2. PMID: 24990854. Abstract
Dimethyl fumarate (BG-12, Tecfidera) - NICE says yes in draft final guidance MS Trust, 11 Jul 2014 Accessed on 16 Jul 2014 from http://www.mstrust.org.uk/news/article.jsp?id=6416.
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate) National Institute for Health and Care Excellence, 27 Aug 2014 Accessed on 2 Sep 2014 from https://www.nice.org.uk/news/press-and-media/NICE-recommends-new-treatment-option-for-multiple-sclerosis-dimethyl-fumarate.
Dimethyl fumarate protects pancreatic islet cells and non-endocrine tissue in L-arginine-induced chronic pancreatitis. Robles L, Vaziri ND, Li S, Masuda Y, Takasu C, Takasu M, Vo K, Farzaneh SH, Stamos MJ, Ichii H PLoS One. 2014; 9(9):e107111. Epub 2014 Sep 08. PMID: 25198679. Abstract
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients Biogen Idec, 11 Sep 2014 Accessed on 13 Sep 2014 from http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2376&M=NewsV2&PID=61997.
Eosinophilic Fasciitis-like Disorder Developing in the Setting of Multiple Sclerosis Therapy. Sheu J, Kattapuram SV, Stankiewicz JM, Merola JF J Drugs Dermatol. 2014 Sep 1; 13(9):1144-7. PMID: 25226017. Abstract
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, et al. J Neurol. 2014 Oct 1. Epub 2014 Oct 01. PMID: 25270680. Abstract
FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF) Forward Pharma, 2013 Accessed on 14 Oct 2014 from http://www.forward-pharma.com/fp187.html.
Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. Kita M, Fox RJ, Gold R, Giovannoni G, Phillips TJ, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, et al. Clin Ther. 2014 Oct 11. PMID: 25315404. Abstract
Dimethyl fumarate protection against collagen II degradation. Li Y, Tang J, Hu Y Biochem Biophys Res Commun. 2014 Oct 8. PMID: 25305493. Abstract
Dimethylfumarate induces apoptosis in human mast cells. Förster A, Preussner LM, Seeger JM, Rabenhorst A, Kashkar H, Mrowietz U, Hartmann K Exp Dermatol. 2013 Sep 23. PMID: 24112621. Abstract
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis. Zhang X, Hay JW, Niu X CNS Drugs. 2014 Oct 19. PMID: 25326785. Abstract
Biogen Idec reports death of patient on its MS pill Weisman R, The Boston Globe, 22 Oct 2014 Accessed on 28 Oct 2014 from http://www.bostonglobe.com/business/2014/10/22/biogen-idec-reports-death-patient-that-had-taken-its-multiple-sclerosis-pill-tecfidera/xrAtOBsxA7eHZN3BB0phxJ/story.html.
Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study. Strassburger-Krogias K, Ellrichmann G, Krogias C, Altmeyer P, Chan A, Gold R Ther Adv Neurol Disord. 2014 Sep; 7(5):232-8. PMID: 25342977. Abstract
Meta-analysis of adverse events in recent randomized clinical trials for dimethil fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis. Zagmutt FJ, Carroll CA Int J Neurosci. 2014 Nov 24. PMID: 25387069. Abstract
Editors' Pick No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G Adv Ther. 2014 Nov; 31(11):1134-54. Epub 2014 Nov 21. PMID: 25414048. Abstract
FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate) US Food and Drug Administration, 25 Nov 2014 Accessed on 2 Dec 2014 from http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm.
Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-κB nuclear translocation and down-regulation of Bcl-xL and XIAP. Tsubaki M, Ogawa N, Takeda T, Sakamoto K, Shimaoka H, Fujita A, Itoh T, Imano M, Satou T, Nishida S Biomed Pharmacother. 2014 Oct; 68(8):999-1005. Epub 2014 Sep 29. PMID: 25443417. Abstract
Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Vego H, Sand KL, Høglund RA, Fallang L-E, Gundersen G, Holmøy T, Maghazachi AA Cell Mol Immunol. 2014 Dec 1. PMID: 25435072. Abstract
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors. Booth L, Cruickshanks N, Tavallai S, Roberts JL, Peery M, Poklepovic A, Dent P Cancer Biol Ther. 2014 Sep 24. PMID: 25482938. Abstract
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, Zhang A, Viglietta V, Fox RJ, the DEFINE and CONFIRM study investigators Eur J Neurol. 2015 Jan 2. PMID: 25557371. Abstract
Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis. Luo H, Bhatt H, Mohamad S, Uhrik E, Sen S, Mathew T, Yousif A J Neurol. 2015 Jan 28. Epub 2015 Jan 28. PMID: 25626723. Abstract
Extensive bilateral lower extremity deep venous thrombosis in a patient on dimethyl fumarate. Ratchford EV, Baldanza TJ, Pardo CA J Neurol. 2014 Apr; 261(4):831-2. Epub 2014 Mar 07. PMID: 24603974. Abstract
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Miller DH, Fox RJ, Phillips TJ, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott C A, Tozer DJ, Macmanus DG, Yousry TA, et al. Neurology. 2015 Feb 13. PMID: 25681448. Abstract
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BAC, Zamvil SS Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e76. Epub 2015 Feb 12. PMID: 25738172. Abstract
Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity. Kunze R, Urrutia A, Hoffmann A, Liu H, Helluy X, Pham M, Reischl S, Korff T, Marti HH Exp Neurol. 2015 Feb 25; 266C:99-111. PMID: 25725349. Abstract
Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus - induced demyelinating disease by modifying Nrf2-Keap1 pathway. Kobayashi K, Tomiki H, Inaba Y, Ichikawa M, Kim BS, Koh C-S Int Immunol. 2015 Feb 26. PMID: 25721871. Abstract
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Viglietta V, Miller D, Bar-Or A, Phillips TJ, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, et al. Ann Clin Transl Neurol. 2015 Feb; 2(2):103-18. Epub 2014 Dec 04. PMID: 25750916. Abstract
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro. Brennan MS, Matos MF, Li B, Hronowski X, Gao B, Juhasz P, Rhodes KJ, Scannevin RH PLoS One. 2015; 10(3):e0120254. Epub 2015 Mar 20. PMID: 25793262. Abstract
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate. Rosenkranz T, Novas M, Terborg C N Engl J Med. 2015 Apr 9; 372(15):1476-1478. PMID: 25839861. Abstract
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R) Nasdaq GlobeNewswire, 14 Apr 2015 Accessed on 21 Apr 2015 from http://globenewswire.com/news-release/2015/04/14/724357/10128835/en/U-S-Patent-Office-Declares-an-Interference-Between-Forward-Pharma-and-Biogen-Regarding-the-Treatment-of-Multiple-Sclerosis-With-480-mg-Daily-Dose-of-DMF-the-Active-Ingredient-in-Te.html.
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients Biogen, 20 Apr 2015 Accessed on 21 Apr 2015 from http://biogen.newshq.businesswire.com/press-release/neurology/tecfidera-dimethyl-fumarate-data-reinforce-strong-sustained-efficacy-newly-d.
Editors' Pick Dimethyl fumarate for multiple sclerosis. Xu Z, Zhang F, Sun FL, Gu KF, Dong S, He D Cochrane Database Syst Rev. 2015; 4:CD011076. Epub 1969 Dec 31. PMID: 25900414. Abstract
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Parodi B, Rossi S, Morando S, Cordano C, Bragoni A, Motta C, Usai C, Wipke BT, Scannevin RH, Mancardi GL, et al. Acta Neuropathol. 2015 Apr 29. Epub 2015 Apr 29. PMID: 25920452. Abstract
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe GlobeNewswire, 27 Apr 2015 Accessed on 12 May 2015 from http://www.nasdaq.com/press-release/forward-pharma-receives-decision-to-grant-from-epo-for-dmf-patent-in-europe-20150427-00684.
Biogen Idec Becomes Biogen Biogen, 23 Mar 2015 Accessed on 7 Apr 2015 from http://biogen.newshq.businesswire.com/press-release/corporate/biogen-idec-becomes-biogen.
Dimethyl fumarate induces necroptosis in colon cancer cells through glutathione depletion/ROS increase/MAPKs activation pathway. Xie X, Zhao Y, Ma C-Y, Xu X-M, Zhang Y-Q, Wang C-G, Jin J, Shen X, Gao J-L, Li N, et al. Br J Pharmacol. 2015 May 8. PMID: 25953698. Abstract
Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2. Zhao X, Sun G, Zhang J, Ting S-M, Gonzales N, Aronowski J Stroke. 2015 May 14. PMID: 25977275. Abstract
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes. Huang H, Taraboletti A, Shriver LP Redox Biol. 2015 Apr 29; 5:169-175. PMID: 25967672. Abstract
Getting a Handle on Lymphopenia With Tecfidera Fiore K, MedPage Today, 2 Jun 2015 Accessed on 8 Jun 2015 from http://www.medpagetoday.com/MeetingCoverage/CMSC/51905.
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. Maruszczak MJ, Montgomery SM, Griffiths MJS, Bergvall N, Adlard N J Med Econ. 2015 Jun 9:1-24. PMID: 26055952. Abstract
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway. Wang Q, Chuikov S, Taitano S, Wu Q, Rastogi A, Tuck SJ, Corey JM, Lundy SK, Mao-Draayer Y Int J Mol Sci. 2015; 16(6):13885-907. PMID: 26090715. Abstract
Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells. Miglio G, Veglia E, Fantozzi R Int Immunopharmacol. 2015 Sep; 28(1):215-9. Epub 2015 Jun 18. PMID: 26096886. Abstract
Biogen Reports Another Tecfidera PML Case Fiore K, MedPage Today, 16 Jul 2015 Accessed on 27 Jul 2015 from http://www.medpagetoday.com/Neurology/MultipleSclerosis/52622.
The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk. Khatri BO, Garland J, Berger J, Kramer J, Sershon L, Olapo T, Sesing J, Dukic M, Rehn E Mult Scler Relat Disord. 2015 Jul; 4(4):377-9. PMID: 26195059. Abstract
Effects of dimethyl fumarate on lymphocyte subsets. Berkovich R, Weiner LP Mult Scler Relat Disord. 2015 Jul; 4(4):339-41. PMID: 26195053. Abstract
Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells. Gerhardt S, König V, Doll M, Hailemariam-Jahn T, Hrgovic I, Zöller N, Kaufmann R, Kippenberger S, Meissner M J Inflamm (Lond). 2015; 12:49. Epub 2015 Aug 06. PMID: 26246800. Abstract
Fumaric Acid Esters Do Not Reduce Inflammatory NF-κB/p65 Nuclear Translocation, ICAM-1 Expression and T-Cell Adhesiveness of Human Brain Microvascular Endothelial Cells. Haarmann A, Nehen M, Deiß A, Buttmann M Int J Mol Sci. 2015; 16(8):19086-95. PMID: 26287168. Abstract
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada. Dorman E, Kansal AR, Sarda S J Med Econ. 2015 Sep 21:1-7. PMID: 26390149. Abstract
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Tramacere I, Giovane C D, Salanti G, D'Amico R, Filippini G Cochrane Database Syst Rev. 2015 Sep 18; 9:CD011381. PMID: 26384035. Abstract
Dimethylfumarate Impairs Neutrophil Functions. Müller S, Behnen M, Bieber K, Möller S, Hellberg L, Witte M, Hänsel M, Zillikens D, Solbach W, Laskay T, et al. J Invest Dermatol. 2015 Oct 5. PMID: 26436330. Abstract
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients Biogen, 7 Oct 2015 Accessed on 13 Oct 2015 from http://media.biogen.com/press-release/neurology/new-data-show-strong-sustained-effects-tecfidera-dimethyl-fumarate-newly-dia.
Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models. Kihara Y, Groves A, Rivera RR, Chun J Ann Clin Transl Neurol. 2015 Oct; 2(10):978-83. Epub 2015 Sep 11. PMID: 26478898. Abstract
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. Phillips TJ, Selmaj K, Gold R, Fox RJ, Havrdova E, Giovannoni G, Abourjaily H, Pace A, Novas M, Hotermans C, et al. Int J MS Care. 2015 Sep-Oct; 17(5):236-43. PMID: 26472945. Abstract
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L Mult Scler. 2015 Oct 12. PMID: 26459150. Abstract
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (INSPIRE) ClinicalTrials.gov, 3 Sep 2015 Accessed on 27 Oct 2015 from https://www.clinicaltrials.gov/ct2/show/NCT02430532.
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance Biogen, 21 Oct 2015 Accessed on 27 Oct 2015 from http://media.biogen.com/press-release/investor-relations/biogen-third-quarter-2015-revenues-increase-11-28-billion-company-r.
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-Related Hospitalizations: Integrated Analysis of the Delayed-Release Dimethyl Fumarate Phase III Studies. Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Sarda SP, Zhang R, Viglietta V, Havrdova E Clin Ther. 2015 Oct 30. PMID: 26526385. Abstract
Mutually enhancing anti-inflammatory activities of dimethyl fumarate and NF-κB inhibitors - Implications for dose-sparing combination therapies. Hund A-C, Lockmann A, Schön MP Exp Dermatol. 2015 Oct 29. PMID: 26513635. Abstract
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH Mult Scler J Exp Transl Clin. 2015 Jan-Dec; 1. Epub 2015 Jul 31. PMID: 26550483. Abstract
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, et al. J Neurol. 2014 Sep; 261(9):1794-802. Epub 2014 Jul 03. PMID: 24989666. Abstract
Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection. Pitarokoili K, Ambrosius B, Meyer D, Schrewe L, Gold R PLoS One. 2015; 10(11):e0143416. Epub 2015 Nov 30. PMID: 26618510. Abstract
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. Patti F, Leone C, Zappia M BMC Neurol. 2015; 15:252. Epub 2015 Dec 07. PMID: 26643473. Abstract
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity. Luchtman D, Gollan R, Ellwardt E, Birkenstock J, Robohm K, Siffrin V, Zipp F J Neurochem. 2015 Dec 10. PMID: 26662167. Abstract
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Gold R, Phillips TJ, Havrdova E, Bar-Or A, Kappos L, Kim N, Thullen T, Valencia P, Oliva L, Novas M, et al. Neurol Ther. 2015 Dec; 4(2):93-104. Epub 2015 Oct 12. PMID: 26662361. Abstract
Fourth PML Case With Tecfidera in MS Calls for Vigilance Hughes S, Medscape, 17 Dec 2015 Accessed on 22 Dec 2015 from http://www.medscape.com/viewarticle/856148.
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion. Cho H, Hartsock MJ, Xu Z, He M, Duh EJ J Neuroinflammation. 2015; 12(1):239. Epub 2015 Dec 21. PMID: 26689280. Abstract
Dimethyl Fumarate Inhibits the Nuclear Factor kappaB Pathway in Breast Cancer Cells by Covalent Modification of p65. Kastrati I, Siklos MA, Calderon-Gierszal EL, El-Shennawy L, Georgieva G, Thayer EN, Thatcher GRJ, Frasor J J Biol Chem. 2015 Dec 18. PMID: 26683377. Abstract
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier. Lim JL, van der Pol SMA, Di Dio F, van Het Hof B, Kooij G, de Vries HE, van Horssen J Microvasc Res. 2015 Dec 8. PMID: 26679389. Abstract
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T J Med Econ. 2015 Dec 26:1-36. PMID: 26707273. Abstract
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'maison F, et al. Eur J Neurol. 2016 Jan 19. PMID: 26782663. Abstract
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis. Michell-Robinson MA, Moore CS, Healy LM, Osso LA, Zorko N, Grouza V, Touil H, Poliquin-Lasnier L, Trudelle A-M, Giacomini PS, et al. Ann Clin Transl Neurol. 2016 Jan; 3(1):27-41. Epub 2015 Dec 02. PMID: 26783548. Abstract
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Gross CC, Schulte-Mecklenbeck A, Klinsing S, Posevitz-Fejfár A, Wiendl H, Klotz L Neurol Neuroimmunol Neuroinflamm. 2016 Feb; 3(1):e183. Epub 2015 Dec 10. PMID: 26767188. Abstract
Fumaric acid esters promote neuronal survival upon ischemic stress through activation of the Nrf2 but not HIF-1 signaling pathway. Lin-Holderer J, Li L, Gruneberg D, Marti HH, Kunze R Neuropharmacology. 2016 Jan 19; 105:228-240. PMID: 26801077. Abstract
Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158N murine oligodendrocytes. Zarrouk A, Nury T, Karym E-M, Vejux A, Sghaier R, Gondcaille C, Andreoletti P, Trompier D, Savary S, Cherkaoui-Malki M, et al. J Steroid Biochem Mol Biol. 2016 Feb 24. PMID: 26921765. Abstract
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE). Fox EJ, Vasquez A, Grainger W, Ma TS, von Hehn C, Walsh J, Li J, Zambrano J Int J MS Care. 2016 Jan-Feb; 18(1):9-18. PMID: 26917993. Abstract
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate. Belcher JD, Chen C, Nguyen J, Zhang P, Abdulla F, Nguyen P, Killeen T, Xu P, O'Sullivan G, Nath K, et al. Antioxid Redox Signal. 2016 Feb 25. PMID: 26914345. Abstract
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Gold R, Giovannoni G, Phillips TJ, Fox RJ, Zhang A, Marantz JL Neurol Ther. 2016 Mar 1. PMID: 26932146. Abstract
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Lundy SK, Wu Q, Wang Q, Dowling CA, Taitano SH, Mao G, Mao-Draayer Y Neurol Neuroimmunol Neuroinflamm. 2016 Apr; 3(2):e211. Epub 2016 Mar 03. PMID: 27006972. Abstract
Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study. Makhani N, Schreiner T Pediatr Neurol. 2016 Apr; 57:101-4. Epub 2016 Jan 20. PMID: 26996405. Abstract
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. Chevalier J, Chamoux C, Hammès F, Chicoye A PLoS One. 2016; 11(3):e0150703. Epub 2016 Mar 17. PMID: 26987055. Abstract
Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. Tavallai M, Booth L, Roberts JL, McGuire WP, Poklepovic A, Dent P Oncotarget. 2016 Mar 12. PMID: 26981780. Abstract
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms. Brennan M S, Patel H, Allaire N, Thai A, Cullen P, Ryan S, Lukashev M, Bista P, Huang R, Rhodes KJ, et al. Antioxid Redox Signal. 2016 Mar 16. PMID: 26980071. Abstract
Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate. Ma BB, Ostrow LW, Newsome SD Neurol Neuroimmunol Neuroinflamm. 2016 Apr; 3(2):e203. Epub 2016 Mar 09. PMID: 27027095. Abstract
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease. Lastres Becker I, Garcia-Yague A J, Scannevin RH, Casarejos M J, Kügler S, Rábano A, Cuadrado A Antioxid Redox Signal. 2016 Mar 23. PMID: 27009601. Abstract
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness Biogen, 18 Apr 2016 Accessed on 19 Apr 2016 from http://media.biogen.com/press-release/neurodegenerative-diseases/tecfidera-data-confirm-strong-and-sustained-efficacy-newly-.
